Premium Nahrungsergänzungsmittel | artgerecht

ANCA-associated Vasculitis: Causes & Treatment

ANCA-associated vasculitis is a rare autoimmune disease in which blood vessels become inflamed. Early diagnosis and treatment are essential to prevent serious organ damage.

Regular tips about health Regular tips about health

Things worth knowing about "ANCA-associated vasculitis"

ANCA-associated vasculitis is a rare autoimmune disease in which blood vessels become inflamed. Early diagnosis and treatment are essential to prevent serious organ damage.

What is ANCA-associated vasculitis?

ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases in which the immune system mistakenly attacks and inflames the walls of small to medium-sized blood vessels. The acronym ANCA stands for anti-neutrophil cytoplasmic antibodies – specific antibodies found in the blood that serve as a hallmark diagnostic feature of this disease group. The inflammation can affect virtually any organ, but the kidneys, lungs, and upper respiratory tract are most commonly involved.

Subtypes of ANCA-associated vasculitis

AAV encompasses three main subtypes:

Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis: primarily affects the airways and kidneys.
Microscopic polyangiitis (MPA): predominantly involves small blood vessels, frequently in the kidneys and lungs.
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome: often associated with asthma and elevated eosinophil counts.

Causes

The exact cause of AAV is not yet fully understood. It is believed that a combination of genetic predisposition and environmental factors – such as infections or exposure to certain chemicals – triggers the disease. ANCA antibodies activate neutrophils (immune cells), which then attack blood vessel walls, causing inflammation and tissue damage.

Symptoms

The symptoms of AAV vary widely depending on which organs are affected. Common symptoms include:

General symptoms: fatigue, fever, weight loss, night sweats
Kidneys: blood in the urine (haematuria), impaired kidney function, potentially leading to kidney failure
Lungs: cough, shortness of breath, coughing up blood (haemoptysis)
Upper respiratory tract: chronic sinusitis, nosebleeds, saddle nose deformity (in GPA)
Skin: purpura (small bleeds beneath the skin surface), ulcers
Nervous system: numbness, tingling, or weakness (mononeuritis multiplex)
Eyes: inflammation, visual disturbances

Diagnosis

The diagnosis of AAV is based on several investigations:

Blood tests: detection of ANCA antibodies (c-ANCA/PR3-ANCA in GPA; p-ANCA/MPO-ANCA in MPA and EGPA), inflammatory markers (CRP, ESR), kidney function tests
Urinalysis: detection of blood or protein in the urine as a sign of kidney involvement
Imaging: chest X-ray or CT scan of the lungs and sinuses
Biopsy: tissue sampling from affected organs (e.g., kidney or lung) for histological confirmation of vasculitis

Treatment

Treatment of AAV follows two main phases:

Remission induction

The goal of this phase is to rapidly suppress active inflammation. Medications used include:

Corticosteroids (e.g., prednisolone) at high doses to quickly reduce inflammation
Cyclophosphamide or rituximab as immunosuppressive agents to dampen the overactive immune response
In life-threatening cases, plasmapheresis (a blood purification procedure) may be added

Remission maintenance

After successful remission induction, treatment continues to prevent relapse:

Azathioprine, methotrexate, or rituximab at lower doses
Gradual tapering of corticosteroids
Regular medical check-ups and laboratory tests to monitor disease activity and medication tolerance

Prognosis and disease course

Thanks to modern therapies, the prognosis of AAV has improved considerably. Many patients achieve stable remission. However, the disease is prone to relapse, making long-term medical follow-up essential. Severe organ damage, particularly to the kidneys, may persist permanently despite treatment.

References

Jennette JC et al. - 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism, 2013.
Hellmich B et al. - EULAR recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2024.
Falk RJ, Gross WL - Anti-neutrophil cytoplasmic autoantibody-associated disease: where do we go from here? Kidney International, 2011.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.